135 related articles for article (PubMed ID: 35182370)
1. Race/Ethnicity may be an Important Predictor of Life Expectancy in Localized Prostate Cancer Patients: Novel Analyses Using Social Security Administration Life Tables.
Würnschimmel C; Nocera L; Wenzel M; Ruvolo CC; Tian Z; Saad F; Briganti A; Shariat SF; Mirone V; Chun FKH; Tilki D; Graefen M; Karakiewicz PI
J Racial Ethn Health Disparities; 2023 Apr; 10(2):708-717. PubMed ID: 35182370
[TBL] [Abstract][Full Text] [Related]
2. Validation of the Social Security Administration Life Tables (2004-2014) in Localized Prostate Cancer Patients within the Surveillance, Epidemiology, and End Results database.
Preisser F; Bandini M; Mazzone E; Nazzani S; Marchioni M; Tian Z; Saad F; Pompe RS; Shariat SF; Heinzer H; Montorsi F; Huland H; Graefen M; Tilki D; Karakiewicz PI
Eur Urol Focus; 2019 Sep; 5(5):807-814. PubMed ID: 29802052
[TBL] [Abstract][Full Text] [Related]
3. Race/Ethnicity Determines Life Expectancy in Surgically Treated T1aN0M0 Renal Cell Carcinoma Patients.
Würnschimmel C; Collà Ruvolo C; Nocera L; Wenzel M; Tian Z; Saad F; Briganti A; Shariat SF; Mirone V; Chun FKH; Tilki D; Graefen M; Karakiewicz PI
Eur Urol Focus; 2022 Jan; 8(1):191-199. PubMed ID: 33610487
[TBL] [Abstract][Full Text] [Related]
4. Long-term overall survival of radical prostatectomy patients is often superior to the general population: A comparison using life-table data.
Würnschimmel C; Wenzel M; Wang N; Tian Z; Karakiewicz PI; Graefen M; Huland H; Tilki D
Prostate; 2021 Aug; 81(11):785-793. PubMed ID: 34101879
[TBL] [Abstract][Full Text] [Related]
5. Life expectancy in metastatic urothelial bladder cancer patients according to race/ethnicity.
Chierigo F; Borghesi M; Würnschimmel C; Flammia RS; Horlemann B; Sorce G; Hoeh B; Tian Z; Saad F; Graefen M; Gallucci M; Briganti A; Montorsi F; Chun FKH; Shariat SF; Mantica G; Suardi N; Terrone C; Karakiewicz PI
Int Urol Nephrol; 2022 Jul; 54(7):1521-1527. PubMed ID: 35508792
[TBL] [Abstract][Full Text] [Related]
6. Life expectancy in metastatic prostate cancer patients according to racial/ethnic groups.
Würnschimmel C; Wenzel M; Collà Ruvolo C; Nocera L; Tian Z; Saad F; Briganti A; Shariat SF; Mirone V; Chun FK; Tilki D; Graefen M; Karakiewicz PI
Int J Urol; 2021 Aug; 28(8):862-869. PubMed ID: 33993551
[TBL] [Abstract][Full Text] [Related]
7. The effect of race/ethnicity on active treatment rates among septuagenarian or older low risk prostate cancer patients.
Nocera L; Wenzel M; Collà Ruvolo C; Würnschimmel C; Tian Z; Gandaglia G; Fossati N; Chun FKH; Mirone V; Graefen M; Shariat SF; Saad F; Montorsi F; Briganti A; Karakiewicz PI
Urol Oncol; 2021 Nov; 39(11):785.e11-785.e17. PubMed ID: 33992522
[TBL] [Abstract][Full Text] [Related]
8. External beam radiation therapy improves survival in high- and intermediate-risk non-metastatic octogenarian prostate cancer patients.
Knipper S; Dzyuba-Negrean C; Palumbo C; Pecoraro A; Rosiello G; Tian Z; Briganti A; Saad F; Tilki D; Graefen M; Karakiewicz PI
Int Urol Nephrol; 2020 Jan; 52(1):59-66. PubMed ID: 31542882
[TBL] [Abstract][Full Text] [Related]
9. Survival advantage of Asian metastatic prostate cancer patients treated with external beam radiotherapy over other races/ethnicities.
Würnschimmel C; Wenzel M; Collà Ruvolo C; Nocera L; Tian Z; Saad F; Briganti A; Shariat SF; Mandel P; Chun FKH; Tilki D; Graefen M; Karakiewicz PI
World J Urol; 2021 Oct; 39(10):3781-3787. PubMed ID: 33978812
[TBL] [Abstract][Full Text] [Related]
10. Cancer-specific mortality after radical prostatectomy vs external beam radiotherapy in high-risk Hispanic/Latino prostate cancer patients.
Hoeh B; Hohenhorst JL; Flammia R; Horlemann B; Sorce G; Chierigo F; Tian Z; Saad F; Graefen M; Gallucci M; Briganti A; Terrone C; Shariat SF; Kluth LA; Becker A; Chun FKH; Karakiewicz PI
Int Urol Nephrol; 2022 Jan; 54(1):81-87. PubMed ID: 34783982
[TBL] [Abstract][Full Text] [Related]
11. External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis.
Moschini M; Zaffuto E; Karakiewicz PI; Andrea DD; Foerster B; Abufaraj M; Soria F; Mattei A; Montorsi F; Briganti A; Shariat SF
Eur Urol; 2019 Feb; 75(2):319-328. PubMed ID: 30293908
[TBL] [Abstract][Full Text] [Related]
12. Comorbidity and age cannot explain variation in life expectancy associated with treatment of non-metastatic prostate cancer.
Boehm K; Dell'Oglio P; Tian Z; Capitanio U; Chun FKH; Tilki D; Haferkamp A; Saad F; Montorsi F; Graefen M; Karakiewicz PI
World J Urol; 2017 Jul; 35(7):1031-1036. PubMed ID: 27796538
[TBL] [Abstract][Full Text] [Related]
13. Racial Differences in the Surgical Care of Medicare Beneficiaries With Localized Prostate Cancer.
Schmid M; Meyer CP; Reznor G; Choueiri TK; Hanske J; Sammon JD; Abdollah F; Chun FK; Kibel AS; Tucker-Seeley RD; Kantoff PW; Lipsitz SR; Menon M; Nguyen PL; Trinh QD
JAMA Oncol; 2016 Jan; 2(1):85-93. PubMed ID: 26502115
[TBL] [Abstract][Full Text] [Related]
14. The Prognosis of Radical Prostatectomy, External Beam Radiotherapy plus Brachytherapy, and External Beam Radiotherapy Alone for Patients above 70 Years with Very High-Risk Prostate Cancer: A Population-Matched Study.
Song P; Shu M; Yang L; Di X; Liu P; Liu Z; Zhou J; Dong Q
Urol Int; 2022; 106(1):11-19. PubMed ID: 34515256
[TBL] [Abstract][Full Text] [Related]
15. The impact of race/ethnicity on upstaging and/or upgrading rates among intermediate risk prostate cancer patients treated with radical prostatectomy.
Nocera L; Wenzel M; Collà Ruvolo C; Würnschimmel C; Tian Z; Gandaglia G; Fossati N; Chun FKH; Mirone V; Graefen M; Saad F; Shariat SF; Montorsi F; Briganti A; Karakiewicz PI
World J Urol; 2022 Jan; 40(1):103-110. PubMed ID: 34436637
[TBL] [Abstract][Full Text] [Related]
16. The Effect of Other-cause Mortality Adjustment on Access to Alternative Treatment Modalities for Localized Prostate Cancer Among African American Patients.
Bandini M; Preisser F; Nazzani S; Marchioni M; Tian Z; Mazzone E; Graefen M; Montorsi F; Shariat SF; Saad F; Briganti A; Karakiewicz PI
Eur Urol Oncol; 2018 Aug; 1(3):215-222. PubMed ID: 31102624
[TBL] [Abstract][Full Text] [Related]
17. Oncologic outcome of radical prostatectomy versus radiotherapy as primary treatment for high and very high risk localized prostate cancer.
Emam A; Hermann G; Attwood K; Ji W; James G; Kuettel M; Mohler JL
Prostate; 2021 Mar; 81(4):223-230. PubMed ID: 33471385
[TBL] [Abstract][Full Text] [Related]
18. Cancer-specific survival after radical prostatectomy versus external beam radiotherapy in high-risk and very high-risk African American prostate cancer patients.
Hoeh B; Würnschimmel C; Flammia RS; Horlemann B; Sorce G; Chierigo F; Tian Z; Saad F; Graefen M; Gallucci M; Briganti A; Terrone C; Shariat SF; Kluth LA; Mandel P; Chun FKH; Karakiewicz PI
Prostate; 2022 Jan; 82(1):120-131. PubMed ID: 34662443
[TBL] [Abstract][Full Text] [Related]
19. Quantifying treatment selection bias effect on survival in comparative effectiveness research: findings from low-risk prostate cancer patients.
Miccio JA; Talcott WJ; Jairam V; Park HS; Yu JB; Leapman MS; Johnson SB; King MT; Nguyen PL; Kann BH
Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):414-422. PubMed ID: 32989262
[TBL] [Abstract][Full Text] [Related]
20. Survival outcomes of radical prostatectomy and external beam radiotherapy in clinically localized high-risk prostate cancer: a population-based, propensity score matched study.
Gu X; Gao X; Cui M; Xie M; Ma M; Qin S; Li X; Qi X; Bai Y; Wang D
Cancer Manag Res; 2018; 10():1061-1067. PubMed ID: 29773955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
